Please login to the form below

Opko

This page shows the latest Opko news and features for those working in and with pharma, biotech and healthcare.

Versartis crashes as VELOCITY trial veers off track

It’s not the first long-acting hGH to miss the mark in trials - earlier this year Pfizer and Opko’s once-weekly candidate also failed a phase III trial.

Latest news

Pfizer/Opko's long-acting growth hormone misses mark in trial

Pfizer and partner Opko ended 2016 on a disappointing note after their long-acting drug for growth hormone deficiency failed a phase III trial. ... Opko put a brave face on the finding, saying it could have been skewed by "one or more outliers" that
Pfizer buys majority stake in Redvax

No financial details of the deal have been disclosed. This rounds off a busy M&A period for Pfizer which just a fortnight ago partnered with Opko Health on a late
RNA interference rebirth

TTR. TTR-mediated amyloidosis. I. TKM-ApoB. Tekmira. ApoB. hypercholesterolaemia. Stalled. bevasiranib. Opko Health.
Flicking the switch

Opko Health is developing bevasiranib for the treatment for wet age-related macular degeneration (AMD). ... In phase II trials, bevasiranib inhibited the growth of choroidal neovascularisation and Opko have now initiated a pivotal phase III trial that
Mastering the gene

Acuity plans to initiate its phase III programme in 2007 and in March the company agreed a merger with several partners to establish a publicly-traded company, Opko. ... If the trial goes as hoped, Opko may lead the race to reach the market with a siRNA

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Deal Watch May 2016

The manufacturing CRLs have been out in force and AstraZeneca is not the only company on the receiving end with OPKO receiving a CRL earlier in the year [March] in relation ... 293. OPKO Health/ Vifor Fresenius. Licence. Rayaldee in EP, CA, Mexico,
Pharma deals in June 2015

Opko's strategy in its $1.47bn acquisition of Bio-Reference Laboratories at $52.58 per share (approximately 60% premium) is to gain access to a range of diagnostic capabilities including ... Acquisition - company. 2, 050. Bio-Reference Laboratories/ OPKO
Pharma deals during December 2014

This product, named hGH-CTP, was in the portfolio of Prolor Biotech which Opko acquired in August 2013 for $480m. ... The upfront payment of $295m from Pfizer will go some of the way to recoup the price Opko paid for Prolor.
Deal Watch table for December 2014

Collaboration, licence. 581. Opko Health / Pfizer. Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

AstraZeneca appoints head of oncology

Prior to this, Dr Freedman served as GlaxoSmithKline's vice president of oncology R&D, and led OPKO Health's R&D department.
OPKO appoints vice president of medical affairs

Dr Douglass Laidlaw brings experience from Relypsa and Sanofi. Miami-based OPKO Health has appointed Dr Douglass Laidlaw as vice president of medical affairs. ... Philip Frost, chairman and chief executive of OPKO, said: “Doug is a key addition to the